Literature DB >> 29117487

Adjuvant Melanoma Therapy - Head-Spinning Progress.

Lynn M Schuchter1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29117487     DOI： 10.1056/NEJMe1711199

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.

Authors:  Drew Pratt; Gifty Dominah; Graham Lobel; Arnold Obungu; John Lynes; Victoria Sanchez; Nicholas Adamstein; Xiang Wang; Nancy A Edwards; Tianxia Wu; Dragan Maric; Amber J Giles; Mark R Gilbert; Martha Quezado; Edjah K Nduom
Journal:  Neurosurgery       Date:  2019-08-01       Impact factor: 4.654

2.  Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation.

Authors:  Luca Quattrini; Vito Coviello; Stefania Sartini; Teresa Di Desidero; Paola Orlandi; Yi-Yu Ke; Kai-Lun Liu; Hsing-Pang Hsieh; Guido Bocci; Concettina La Motta
Journal:  Sci Rep       Date:  2019-07-09       Impact factor: 4.379

3.  An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.

Authors:  Arielle G Bensimon; Zheng-Yi Zhou; Madeline Jenkins; Yan Song; Wei Gao; James Signorovitch; Clemens Krepler; Emilie Scherrer; Jingshu Wang; Raquel Aguiar-Ibáñez
Journal:  Clin Drug Investig       Date:  2020-07       Impact factor: 2.859

4.  Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study.

Authors:  Frances Rapport; Andrea L Smith; Anne E Cust; Graham J Mann; Caroline G Watts; David E Gyorki; Michael Henderson; Angela M Hong; John W Kelly; Georgina V Long; Victoria J Mar; Rachael L Morton; Robyn Pm Saw; Richard A Scolyer; Andrew J Spillane; John F Thompson; Jeffrey Braithwaite
Journal:  BMJ Open       Date:  2020-02-27       Impact factor: 2.692
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.